Biotalys Moves Closer to California Approval for Biofungicide EVOCA
Event summary
- Biotalys' biofungicide EVOCA enters public consultation phase in California, a key step toward regulatory approval.
- CDPR's Human Health Assessment Branch recommended registration based on submitted data.
- California's 30-day comment period ends July 26; final decision expected in H2 2026.
- EVOCA targets fungal diseases in fruit and vegetable crops, with EVOCA NG planned for U.S. launch in 2029.
The big picture
Biotalys' progress in California underscores the growing demand for sustainable crop protection solutions. As regulatory hurdles clear, the company positions itself to challenge traditional chemical fungicides with protein-based alternatives. Success here could accelerate adoption across major agricultural markets, reinforcing Biotalys' leadership in biocontrol innovation.
What we're watching
- Regulatory Momentum
- Whether Biotalys can secure California approval by H2 2026, following Florida's earlier approval.
- Market Expansion
- The pace at which EVOCA gains traction in the $1.1B U.S. and European biofungicide market.
- Technological Validation
- How AGROBODY® platform's success with EVOCA influences investor confidence in Biotalys' pipeline.
Related topics